Sarcopenia Musculoskeletal Diseases Sarcopenia
Conditions
Interventions
Participants are randomly allocated to one of two groups, and receive a set of meal plans to follow for two weeks. Participants are randomised in advance by a UHB statistician using a computer generat
we will take small samples from participants’ thigh muscles at the start and end of the study, as well as saliva samples, and participants will drink a small amount of water containing a tracer molecu
Sponsors
University of Birmingham
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 65 years or over 2. Female 3. Ambulatory (with or without walking aids)
Exclusion criteria
Exclusion criteria: 1. Already engaging in regular exercise (at least twice a week) 2. History of myocardial infarction within previous 2 years 3. Cardiac illness: moderate/ severe aortic stenosis, acute pericarditis, acute myocarditis, aneurysm, severe angina, 4. Clinically significant valvular disease, uncontrolled dysrhythmia, claudication within the previous 10 years 5. Thrombophlebitis or pulmonary embolus within the previous 2 years 6. History of cerebrovascular disease (CVA or TIA) within the previous 2 years 7. Treatment with anticoagulants (Warfarin, rivaroxaban, apixaban, dabigatran) and antiplatelets (dipyridamole, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa antagonists). Nb. those regularly taking aspirin will be asked to stop for 3 days prior to biopsies and restart the day after 8. Acute febrile illness within the previous 3 months 9. Severe airflow obstruction 10. Uncontrolled metabolic disease (e.g., thyroid disease or cancer) 11. Significant emotional distress, psychotic illness or depression within the previous 2 years 12. Lower limb fracture sustained within the previous 2 years; upper limb fracture within the previous 6 months; non arthroscopic lower limb joint surgery within the previous 2 years 13. Any reason for loss of mobility for greater than 1 week in the previous 2 months or greater than 2 weeks in the previous 6 months 14. Resting systolic pressure >200 mmHg or resting diastolic pressure >100mmHg 15. Poorly controlled atrial fibrillation 16. Poor (chronic) pain control 17. Moderate/ severe cognitive impairment (MMSE <23) 18. Renal impairment (Stage 4 or 5)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle protein synthesis is measured using D2O tracer, muscle biopsies and saliva samples at baseline and day 14 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Leg extension strength is measured using 1-RM tests at baseline and day 14 2. Serum inflammatory markers IL-1, IL-6, IL-8, TNF-alpha, and the anti-inflammatory cytokine IL-10, are measured using blood samples taken at baseline and day 14 3. Compliance to diet intervention is measured using self-reported records of daily compliance to meal plans, and 3-day food diary between days 7 and 14 | — |
Countries
United Kingdom
Contacts
Public ContactCarolyn Greig
Outcome results
None listed